The CDK7 inhibitor YKL-5-124 activates proinflammatory IFNγ signaling and predominantly disrupts cell cycle progression, causing DNA replication stress and genome instability in small-cell lung cancer (SCLC), while simultaneously triggering immune response signaling and provoking T-cell responses.47 Interestingly, LSD1 inhibition resulted in elevated IFNγ production in T cells as well as G0/G1 cell cycle arrest, while restricting the transition to the S-phase, which mostly involved DNA replication. Here, CDK7 is linked to small cell lung carcinoma.